investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

The interaction of Burkitt's lymphoma Cofactors EBV and Plasmodium

Eric M Wohlford

1 Collaborator(s)

Funding source

National Cancer Institute (NIH)
Endemic Burkitt's lymphoma (eBL) is the most common pediatric cancer in sub-Saharan Africa. Endemic BL is an aggressive B cell lymphoma with two infectious cofactors: early Epstein Barr virus (EBV) infection and frequent Plasmodium falciparum malaria. Recent research suggests that P. falciparum parasites increase the lytic activation of EBV from B cell lines. It was shown that P. falciparum parasites exert their effect o EBV through polyclonal activation B cells. Plasmodium falciparum parasites contain multiple polyclonal B cell activators, including CpG DNA, which stimulates toll-like receptor 9 (TLR9). It was recently shown that activation of B cells using CpG oligonucleotide sequences increased the infection and EBV-induced proliferation of B cells. It has not been shown, however, whether P. falciparum parasites increase the primary EBV infection and EBV-induced proliferation of B cells. Our preliminary in vitro and in vivo studies suggest that P. falciparum indeed increases these measures. We observed an increased frequency of EBV infected cells in children in a high malaria area compared to those in a nearby low malaria area of western Kenya by quantitative PCR. To further determine the interaction of P. falciparum and EBV in regard to eBL we have proposed the following studies. We will complete an in vitro study to determine the effects of P. falciparum on the establishment of EBV latency. We hypothesize that exposure to P. falciparum parasites will increase the EBV-induced proliferation, EBV load, or alter the EBV infected B cell phenotype of B cells in vitro. We will also translate our work to the clinic by performing an acute P. falciparum malaria field study in western Kenya to determine whether P. falciparum malaria activates B cells and increases their susceptibility to EBV infection in vivo. We will compare the B cell activation and EBV infection of individual B cells from P. falciparum malaria patients and healthy controls. This will allow us to make conclusions about which B cell type harbors the increased EBV we observed with our preliminary studies. Overall, this work will determine the interaction of P. falciparum and EBV with the goal of discovering preventative strategies for eBL.

Related projects